1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/24247
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBamias, A.en
dc.contributor.authorKarina, M.en
dc.contributor.authorPapakostas, P.en
dc.contributor.authorKostopoulos, I.en
dc.contributor.authorBobos, M.en
dc.contributor.authorVourli, G.en
dc.contributor.authorSamantas, E.en
dc.contributor.authorChristodoulou, Chen
dc.contributor.authorPentheroudakis, G.en
dc.contributor.authorPectasides, D.en
dc.contributor.authorDimopoulos, M. A.en
dc.contributor.authorFountzilas, G.en
dc.date.accessioned2015-11-24T19:39:27Z-
dc.date.available2015-11-24T19:39:27Z-
dc.identifier.issn1432-0843-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/24247-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic useen
dc.subjectCarboplatin/administration & dosage/adverse effectsen
dc.subjectChemotherapy, Adjuvanten
dc.subjectCisplatin/administration & dosage/adverse effectsen
dc.subjectCombined Modality Therapyen
dc.subjectDiarrhea/chemically induceden
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectImmunohistochemistryen
dc.subjectKaplan-Meier Estimateen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectNeutropenia/chemically induceden
dc.subjectPrognosisen
dc.subjectReceptor, Epidermal Growth Factor/analysisen
dc.subjectReceptor, erbB-2/analysisen
dc.subjectStomach Neoplasms/*drug therapy/metabolism/pathology/*radiotherapyen
dc.subjectTaxoids/administration & dosage/adverse effectsen
dc.subjectTissue Array Analysisen
dc.subjectTreatment Outcomeen
dc.subjectTumor Markers, Biological/analysisen
dc.titleA randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric canceren
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1007/s00280-010-1256-6-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/20130877-
heal.identifier.secondaryhttp://www.springerlink.com/content/q3r40k344751232t/fulltext.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2010-
heal.abstractThe optimal adjuvant treatment for gastric cancer remains controversial. We compared the efficacy of a docetaxel and platinum adjuvant chemotherapy regimen, in patients with high-risk gastric cancer, with that of the same chemotherapy plus radiation therapy (RT). In addition, we evaluated the prognostic and/or predictive value of a panel of molecular markers. Patients with histologically proven, radically resected gastric cancer, stage > or =T3 and/or N+ were randomized to 6 cycles of docetaxel with cisplatin, both at 75 mg/m2 every 3 weeks (arm A) or the same treatment with RT (arm B; 45 Gy). Due to excessive nausea and vomiting, cisplatin was substituted by carboplatin at AUC (area under the curve) of 5 after the first 45 patients (22 group A, 23 group B). The prognostic value of EGFR, ERCC1, HER2, MET/HGFR, MAP-Tau, and PTEN expression was also studied in a subset of 67 patients using immunohistochemistry on tissue microarrays (TMAs). A total of 147 patients were randomized. After a median follow-up of 53.7 months, no differences in overall (OS) and disease-free survival (DFS) were found between the two arms. The most common grade 3/4 toxicities for arms A and B (excluding alopecia) were non-febrile neutropenia (11 and 17%, respectively), febrile neutropenia (9 and 7%) and diarrhea (7 and 4%, respectively). Patients with ERCC1 positive tumors had significantly longer median DFS (33.1 vs. 11.8 months, Wald P = 0.016) and OS (63.2 vs. 18.8 months, Wald P = 0.046). Our results indicate that the addition of RT to platinum/docetaxel adjuvant chemotherapy does not appear to improve survival in high-risk, radically resected gastric cancer. However, the possibility that a benefit by the addition of RT was not detected due to decreased power of the study should not be excluded.en
heal.journalNameCancer Chemother Pharmacolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Bamias-2010-A randomized phase I.pdf640 kBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons